GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.970
- +0.020+1.03%
Close Jan 24 16:00 ET
- 1.970
- 0.0000.00%
Post 16:01 ET
98.12MMarket Cap-0.64P/E (TTM)
1.985High1.940Low90.51KVolume1.960Open1.950Pre Close177.94KTurnover0.30%Turnover RatioLossP/E (Static)49.81MShares20.22052wk High0.53P/B60.46MFloat Cap1.55052wk Low--Dividend TTM30.69MShs Float24.420Historical High--Div YieldTTM2.31%Amplitude1.550Historical Low1.966Avg Price1Lot Size
Trending Stocks
Discussing
As Tesla's earnings near, will its stock soar?
🎙️Discussion: 1. With Trump's return, can Tesla's stock price continue to rise in 2025? 2. Tesla is set to release its earnings report aft
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
HilleVax Stock Forum
📊⚡️📊
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
No comment yet